You are now leaving the Lilly Medical website
The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Lilly USA, LLC does not control, influence, or endorse this site, and the opinions, claims, or comments expressed on this site should not be attributed to Lilly USA, LLC. Lilly USA, LLC is not responsible for the privacy policy of any third-party websites. We encourage you to read the privacy policy of every website you visit.
Click "Continue" to proceed or "Return" to return to Lilly Medical
If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Omvoh ® (mirikizumab-mrkz) injection
300 mg/15 mL, 100 mg/mL
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
Is laboratory monitoring required when a patient is taking Omvoh® (mirikizumab-mrkz)?
Evaluate liver enzymes and bilirubin at baseline and for at least 24 weeks of treatment with mirikizumab. Monitor thereafter according to routine patient management.
Laboratory Monitoring
The prescribing information for mirikizumab does not have a recommendation for other laboratory monitoring, including the monitoring of albumin or prealbumin levels or serum concentrations of mirikizumab.
Enclosed Prescribing Information
Date of Last Review: January 15, 2025